Product
Our Product: MyopiaX®
MyopiaX® is a smartphone application that administers a therapeutic intervention developed to slow the progression of myopia in children and adolescents. Used together with a virtual reality headset and a Bluetooth controller, MyopiaX® is an innovative, non-invasive approach to control myopia that is engaging and easy for children to use.
Use the MyopiaX® app to start a session, keep track of usage and performance to optimize treatment, and much more. Each session with MyopiaX® delivers selective ocular light stimulation on top of the virtual reality game. The goal is to activate the eye’s growth regulation mechanism to slow the progression of myopia. Learn more about how MyopiaX® works on our Science page.
Our App
MyopiaX® is designed for everyday life, leveraging consumer technology to administer selective ocular light stimulation through an interactive digital experience. Developed to deliver an active treatment, MyopiaX® adheres to medical device regulations. MyopiaX®’s intuitive digital platform makes at-home use a breeze, transforming twice daily treatment sessions into an engaging, child-friendly routine.
Child-Friendly Alternative
Informed by feedback from usability studies with children and their families, MyopiaX® is specifically tailored to meet the needs of children. By leveraging consumer electronics and a range of engaging digital content, we envision MyopiaX® as an accessible and enjoyable treatment to slow the progression of myopia. Usability studies with children and their families confirmed that MyopiaX® is fun and easy for children to use under minimal supervision. Our extensive usability engineering studies exceed the standard requirements to evaluate the usability of a medical device as it relates to safety. These studies have been central to the continuous improvement of technical components of the app, as well as the overall user experience of MyopiaX®.
Developed According to Medical Device Standards
MyopiaX® has been designed and developed in accordance with medical device standards of safety related to everyday use. MyopiaX® is accompanied by comprehensive technical documentation that takes into consideration all relevant norms, including those for software lifecycle management (EN 62304) and risk management (ISO 14971). Our goal is to be certified as a medical device under European and other medical device regulations. The results of our ongoing research and clinical trial will inform regulatory activities to obtain certification of MyopiaX® as a medical device.
More About MyopiaX®
MyopiaX® is designed to be used daily. Each session lasts for several minutes and delivers selective ocular light stimulation while users interact with virtual reality content. The virtual reality content includes mini-games, a customizable avatar, and interactive quests. A variety of fun and educational content means that MyopiaX® is always engaging for users.
Our Partners
Dopavision is funded as part of the BMBF’s Industry-in-Clinic Platform Program (FKZ: 13GW0625)